Truist Financial Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to Strong-Buy

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by Truist Financial to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

COLL has been the subject of several other research reports. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Weiss Ratings cut Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Down 1.3%

NASDAQ COLL opened at $34.19 on Monday. Collegium Pharmaceutical has a 52 week low of $29.11 and a 52 week high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The business’s fifty day simple moving average is $34.03 and its 200-day simple moving average is $40.42. The firm has a market cap of $1.11 billion, a PE ratio of 16.76 and a beta of 0.75.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. During the same quarter in the prior year, the firm posted $1.49 earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 6.76 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This trade represents a 15.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.85% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Group One Trading LLC acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Collegium Pharmaceutical during the 4th quarter valued at about $61,000. PNC Financial Services Group Inc. grew its position in Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.